New Opportunities of Dupilumab in Achieving Disease Control in Preschool Age Patients with Atopic Dermatitis: Clinical Case

Background. Atopic dermatitis (AD) is one of the most common chronic inflammatory skin diseases in children. It manifests during the first year of life in majority of cases. Early AD manifestation is a risk factor for the development of other atopic spectrum diseases in the future. Nowadays, the ability of the dupilumab, as a genetically engineered biologic drug (GEBD), to modify the disease course, to reduce the frequency of AD persistence and the possibility of multimorbid atopic phenotype development is widely discussed. Thus, dupilumab management in young children with early onset and severe course arouses specific interest. Clinical case description. This article demonstrates the experience of effective administration of GEBD dupilumab in 4-year old patient with severe AD and comorbid food allergies. Continuous therapy for 12 weeks allowed to recover disease’s skin manifestations. No adverse events were reported. Conclusion. Long-term continuous dupilumab administration in children aged from 6 months to 5 years has proven its efficacy and acceptable safety profile. The potential disease-modifying effect of dupilumab is especially significant for young and preschool children due to the high risk atopic multimorbidity developing during this period.

1. Atopicheskii dermatit u detei: Clinical guidelines. Union of Pediatricians of Russia; Russian Association of Allergists and Clinical Immunologists; Russian Society of Dermatovenerologists and Cosmetologists. Moscow; 2021. 81 p. (In Russ). Доступно по: https://cr.minzdrav.gov.ru/schema/265_2. Ссылка активна на 22.07.2024.

2. Bylund S, Kobyletzki LB, Svalstedt M, Svensson Å. Prevalence and Incidence of Atopic Dermatitis: A Systematic Review. Acta Derm Venereol. 2020;100(12):adv00160. doi: https://doi.org/10.2340/00015555-3510

3. Ambarchian ET, Namazova-Baranova LS, Kuzminova AD, et al. Controversial Issues of Immunopathogenesis of Psoriasis and Atopic Dermatitis. Annals of the Russian academy of medical sciences. 2023;78(6):582–588. doi: https://doi.org/10.15690/vramn9965

4. Çetinarslan T, Kümper L, Fölster-Holst R. The immunological and structural epidermal barrier dysfunction and skin microbiome in atopic dermatitis-an update. Front Mol Biosci. 2023;10:1159404. doi: https://doi.org/10.3389/fmolb.2023.1159404

5. Yang L, Fu J, Zhou Y. Research Progress in Atopic March. Front Immunol. 2020;11:1907. doi: https://doi.org/10.3389/fimmu.2020.01907

6. Paller AS, Spergel JM, Mina-Osorio P, Irvine AD. The atopic march and atopic multimorbidity: many trajectories, many pathways. J Allergy Clin Immunol. 2019;143(1):46–55. doi: https://doi.org/10.1016/j.jaci.2018.11.006

7. Furue M, Ulzii D, Vu YH, et al. Pathogenesis of Atopic Dermatitis: Current Paradigm. Iran J Immunol. 2019;16(2):97–107. doi: https://doi.org/10.22034/IJI.2019.80253

8. Hönzke S, Wallmeyer L, Ostrowski A, et al. Influence of Th2 Cytokines on the Cornified Envelope, Tight Junction Proteins, and ß-Defensins in Filaggrin-Deficient Skin Equivalents. J Invest Dermatol. 2016;136(3):631–639. doi: https://doi.org/10.1016/j. jid.2015.11.007

9. Huang IH, Chung WH, Wu PC, Chen CB. JAK-STAT signaling pathway in the pathogenesis of atopic dermatitis: An updated review. Front Immunol. 2022;13:1068260. doi: https://doi.org/10.3389/fimmu.2022

10. Dubin C, Del Duca E, Guttman-Yassky E. The IL-4, IL-13 and IL-31 pathways in atopic dermatitis. Expert Rev Clin Immunol. 2021;17(8):835–852. doi: https://doi.org/10.1080/1744666X.2021.1940962

11. Stefanovic N, Irvine AD. Filaggrin and beyond: New insights into the skin barrier in atopic dermatitis and allergic diseases, from genetics to therapeutic perspectives. Ann Allergy Asthma Immunol. 2024;132(2): 187–195. doi: https://doi.org/10.1016/j.anai.2023.09.009

12. Schmitt J, Spuls PI, Thomas KS, et al. The Harmonising Outcome Measures for Eczema (HOME) statement to assess clinical signs of atopic eczema in trials. J Allergy Clin Immunol. 2014;134(4): 800–807. doi: https://doi.org/10.1016/j.jaci.2014.07.043

13. Lewis-Jones MS, Finlay AY, Dykes PJ. The Infants’ Dermatitis Quality of Life Index. Br J Dermatol. 2001;144(1):104–110. doi: https://doi.org/10.1046/j.1365-2133.2001.03960.x

14. Wollenberg A, Kinberger M, Arents B, et al. European guideline (EuroGuiDerm) on atopic eczema — part II: non-systemic treatments and treatment recommendations for special AE patient populations. J Eur Acad Dermatol Venereol. 2022;36(11):1904–1926. doi: https://doi.org/10.1111/jdv.18429

15. Wollenberg A, Kinberger M, Arents B, et al. European guideline (EuroGuiDerm) on atopic eczema: part I — systemic therapy. J Eur Acad Dermatol Venereol. 2022;36(9):1409–1431. doi: https://doi.org/10.1111/jdv.18345

16. Olbrich H, Sadik CD, Ludwig RJ, et al. Dupilumab in Inflammatory Skin Diseases: A Systematic Review. Biomolecules. 2023;13(4):634. doi: https://doi.org/10.3390/biom13040634

17. Paller AS, Simpson EL, Siegfried EC, et al. Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebocontrolled, phase 3 trial. Lancet. 2022;400(10356):908–919. doi: https://doi.org/10.1016/S0140-6736(22)01539-2

18. Lin TL, Fan YH, Fan KS, et al. Reduced atopic march risk in pediatric atopic dermatitis patients prescribed dupilumab versus conventional immunomodulatory therapy: A population-based cohort study. J Am Acad Dermatol. 2024:S0190- 9622(24)00788-6. doi: https://doi.org/10.1016/j. jaad.2024.05.029

19. Agache I, Akdis CA, Akdis M, et al. EAACI Biologicals Guidelines-dupilumab for children and adults with moderate-to-severe atopic dermatitis. Allergy. 2021;76(4):988–1009. doi: https://doi.org/10.1111/all.14690

20. Paternoster L, Savenije OEM, Heron J, et al. Identification of atopic dermatitis subgroups in children from 2 longitudinal birth cohorts. J Allergy Clin Immunol. 2018;141(3):964–971. doi: https://doi.org/10.1016/j.jaci.2017.09.044

21. Tran MM, Lefebvre DL, Dharma C, et al. Predicting the atopic march: Results from the Canadian Healthy Infant Longitudinal Development Study. J Allergy Clin Immunol. 2018;141(2):601–607. e8. doi: https://doi.org/10.1016/j.jaci.2017.08.024

22. Lack G. Epidemiologic risks for food allergy. J Allergy Clin Immunol. 2008;121(6):1331–1336. doi: https://doi.org/10.1016/j.jaci.2008.04.032. PMID: 18539191

23. Strid J, Hourihane J, Kimber I, et al. Disruption of the stratum corneum allows potent epicutaneous immunization with protein antigens resulting in a dominant systemic Th2 response. Eur J Immunol. 2004;34(8):2100–2109. doi: https://doi.org/10.1002/eji.200425196

24. Gandhi NA, Bennett BL, Graham NM, et al. Targeting key proximal drivers of type 2 inflammation in disease. Nat Rev Drug Discov. 2016;15(1):35–50. doi: https://doi.org/10.1038/nrd4624

25. Bieber T. In search of the Holy Grail in atopic dermatitis: Will dupilumab become the first disease-modifying atopic dermatitis drug? J Allergy Clin Immunol. 2023;151(3):694–696. doi: https://doi.org/10.1016/j.jaci.2022.12.824

26. Geba GP, Li D, Xu M, et al. Attenuating the atopic march: Metaanalysis of the dupilumab atopic dermatitis database for incident allergic events. J Allergy Clin Immunol. 2023;151(3):756–766. doi: https://doi.org/10.1016/j.jaci.2022.08.026

27. Paller AS, Siegfried EC, Simpson EL, et al. Dupilumab Safety and Efficacy up to 1 Year in Children Aged 6 Months to 5 Years with Atopic Dermatitis: Results from a Phase 3 Open-Label Extension Study. Am J Clin Dermatol. 2024;25(4):655–668. doi: https://doi. org/10.1007/s40257-024-00859-y

28. Paller AS, Siegfried EC, Cork MJ, et al. Laboratory Safety from a Randomized 16-Week Phase III Study of Dupilumab in Children Aged 6 Months to 5 Years with Moderate-to-Severe Atopic Dermatitis. Paediatr Drugs. 2023;25(1):67–77. doi: https://doi.org/10.1007/ s40272-022-00553-8

29. Paller AS, Siegfried EC, Cork MJ, et al. Infections in Children Aged 6 Months to 5 Years Treated with Dupilumab in a Placebo-Controlled Clinical Trial of Moderate-to-Severe Atopic Dermatitis. Paediatr Drugs. 2024;26(2):163–173. doi: https://doi.org/10.1007/s40272-023-00611-9

30. Berna-Rico E, Fiz-Benito E, Busto-Leis JM, et al. Effectiveness and Safety of Dupilumab in Children Under 6 Years of Age with Moderate-to-Severe Atopic Dermatitis: A Retrospective Real-World Study. Dermatology. 2024;240(2):337–342. doi: https://doi.org/10.1159/000535282